A
Anete Trajman
Researcher at Rio de Janeiro State University
Publications - 42
Citations - 2710
Anete Trajman is an academic researcher from Rio de Janeiro State University. The author has contributed to research in topics: Medicine & Tuberculosis. The author has an hindex of 18, co-authored 22 publications receiving 2106 citations. Previous affiliations of Anete Trajman include BC Centre for Disease Control & Federal University of Rio de Janeiro.
Papers
More filters
Journal ArticleDOI
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.
Mayara Lisboa Bastos,Mayara Lisboa Bastos,Gamuchirai Tavaziva,S.K. Abidi,Jonathon R. Campbell,Jonathon R. Campbell,Louis-Patrick Haraoui,James C. Johnston,Zhiyi Lan,Stephanie Law,Emily MacLean,Anete Trajman,Anete Trajman,Dick Menzies,Dick Menzies,Andrea Benedetti,Andrea Benedetti,Faiz Ahmad Khan,Faiz Ahmad Khan +18 more
TL;DR: Higher quality clinical studies assessing the diagnostic accuracy of serological tests for covid-19 are urgently needed, as available evidence does not support the continued use of existing point-of-care serological Tests for coronavirus disease-2019.
Journal ArticleDOI
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Nafees Ahmad,Shama D. Ahuja,Onno W. Akkerman,Jan-Willem C. Alffenaar,Laura F Anderson,Parvaneh Baghaei,Didi Bang,Pennan M. Barry,Mayara Lisboa Bastos,Digamber Behera,Andrea Benedetti,Gregory P. Bisson,Martin J. Boeree,Maryline Bonnet,Sarah K. Brode,James C.M. Brust,Ying Cai,Eric Caumes,J. Peter Cegielski,Rosella Centis,Pei-Chun Chan,Edward D. Chan,Kwok-Chiu Chang,Macarthur Charles,Andra Cirule,Margareth Pretti Dalcolmo,Lia D'Ambrosio,Gerard de Vries,Keertan Dheda,Aliasgar Esmail,Jennifer Flood,Gregory J. Fox,Mathilde Fréchet-Jachym,Geisa Fregona,Regina Gayoso,Medea Gegia,Maria Tarcela Gler,Sue Gu,Lorenzo Guglielmetti,Timothy H. Holtz,Jennifer Hughes,Petros Isaakidis,Leah G. Jarlsberg,Russell R. Kempker,Salmaan Keshavjee,Faiz Ahmad Khan,Maia Kipiani,Serena P. Koenig,Won-Jung Koh,Afranio Lineu Kritski,Liga Kuksa,Charlotte Kvasnovsky,Nakwon Kwak,Zhiyi Lan,Christoph Lange,Rafael Laniado-Laborín,Myungsun Lee,Vaira Leimane,Chi-Chiu Leung,Eric Chung Ching Leung,Pei Zhi Li,Phil Lowenthal,Ethel Leonor Noia Maciel,Suzanne M. Marks,Sundari Mase,Lawrence Mbuagbaw,Giovanni Battista Migliori,Vladimir Milanov,Ann C. Miller,Carole D. Mitnick,Chawangwa Modongo,Erika Mohr,Ignacio Monedero,Payam Nahid,Norbert Ndjeka,Max R. O'Donnell,Nesri Padayatchi,Domingo Palmero,Jean W. Pape,Laura Jean Podewils,Ian R Reynolds,Vija Riekstina,Jérôme Robert,Maria I. Rodriguez,Barbara Seaworth,Kwonjune J. Seung,Kathryn Schnippel,Tae Sun Shim,Rupak Singla,Sarah Smith,Giovanni Sotgiu,Ganzaya Sukhbaatar,Payam Tabarsi,Simon Tiberi,Anete Trajman,Lisa Trieu,Zarir F Udwadia,Tjip S. van der Werf,Nicolas Veziris,Piret Viiklepp,Stalz Charles Vilbrun,Kathleen F. Walsh,Janice Westenhouse,Wing Wai Yew,Jae-Joon Yim,Nicola M. Zetola,Matteo Zignol,Dick Menzies +107 more
TL;DR: Treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis, and the need for trials to ascertain the optimal combination and duration of these drugs is emphasised.
Journal ArticleDOI
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Dick Menzies,Menonli Adjobimey,Rovina Ruslami,Anete Trajman,Oumou Sow,Hee Jin Kim,Joseph Obeng Baah,Guy B. Marks,Richard Long,Vernon Hoeppner,Kevin Elwood,Hamdan Al-Jahdali,M. Gninafon,Lika Apriani,Raspati C Koesoemadinata,Afranio Lineu Kritski,Valeria Cavalcanti Rolla,Boubacar Bah,Alioune Camara,Isaac Boakye,Victoria J. Cook,Hazel Goldberg,Chantal Valiquette,Karen Hornby,Marie-Josée Dion,Pei-Zhi Li,Philip C. Hill,Kevin Schwartzman,Andrea Benedetti +28 more
TL;DR: The 4‐ month regimen of rifampin was not inferior to the 9‐month regimen of isoniazid for the prevention of active tuberculosis and was associated with a higher rate of treatment completion and better safety.
Journal ArticleDOI
Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Dick Menzies,Richard Long,Anete Trajman,Marie-Josée Dion,Jae Yang,Hamdan Al Jahdali,Ziad A. Memish,Kamran Khan,Michael Gardam,Vernon Hoeppner,Andrea Benedetti,Kevin Schwartzman +11 more
TL;DR: A multicenter, randomized trial to compare the frequency of serious adverse events and treatment completion rates in patients given 4 months of daily rifampin or 9 months ofdaily isoniazid for latent tuberculosis infection.
Journal ArticleDOI
Novel tests for diagnosing tuberculous pleural effusion: what works and what does not?
Anete Trajman,Madhukar Pai,Keertan Dheda,R van Zyl Smit,Alice Zwerling,Rajnish Joshi,Shriprakash Kalantri,Peter Daley,Dick Menzies +8 more
TL;DR: An overview of the performance of new diagnostic tests, including markers of specific and nonspecific immune response, nucleic acid amplification and detection, and predictive models based on combinations of markers for pleural tuberculosis are provided.